Current status and prospects of IL-6–targeting therapy
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2097905
Abstract: ABSTRACT Introduction Persistent and excess IL-6 production often contributes to a variety of immune diseases. IL-6–targeting therapy was first approved for Castleman disease, then rheumatoid arthritis, and now it is broadly used. Furthermore, it has… read more here.
Keywords: disease; therapy; prospects targeting; status prospects ... See more keywords
Medicinal prospects of targeting tyrosinase: A feature review.
Sign Up to like & getrecommendations! Published in 2022 at "Current medicinal chemistry"
DOI: 10.2174/0929867329666220915123714
Abstract: Tyrosinase is a bifunctional polyphenol oxidase (PPO), catalyzing two oxidative reactions: monophenols to o-quinones (monophenolase activity) and o-diphenols to o-quinones (diphenolase activity). As tyrosinase is the rate-limiting enzyme for the melanogenesis process, it is an… read more here.
Keywords: medicinal prospects; feature review; prospects targeting; activity ... See more keywords